Therapies for symptomatic primary osteoporosis.
There is no universally accepted pharmacologic treatment for primary symptomatic osteoporosis. However, three agents discussed in this review show varying degrees of promise. Calcitonin increases bone density and has the added benefit of analgesic properties. Etidronate disodium, a diphosphonate approved for symptomatic Paget's disease, has been shown to increase bone density and decrease fractures in osteoporosis. Sodium fluoride, although an effective stimulator of bone growth in low turnover osteoporosis, has been associated with toxicity and increased fractures.
Department of Endocrinology, Cleveland Clinic Foundation, OH.
A A
AA
Licata
D000368:Aged; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003937:Diagnosis, Differential; D012968:Etidronic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D012969:Sodium Fluoride; D002116:Calcitonin; D012968:Etidronic Acid